New pain drug could cut opioid use after stomach surgery
NCT ID NCT07330063
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 22 times
Summary
This study tests a new painkiller called anrikefon in 114 people recovering from laparoscopic stomach cancer surgery. The drug aims to control pain with fewer side effects like nausea and drowsiness than standard opioids. Researchers will measure how much extra opioid pain medicine patients need and how well they tolerate the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, 不限, 300000, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anrikefon (Anruikefen)
What this could lead to
If successful, anrikefon could offer a safer way to manage pain after stomach surgery, with fewer side effects like nausea and less need for strong opioids.
What could go wrong
This is a small, early-stage trial (Phase 2) with only 114 participants. The drug is already approved in China for abdominal surgery pain, but results may not apply to all patients or settings.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.